Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3‐Way Crossover Trial
Clinical Pharmacology & Therapeutics · 2026
DOI: 10.1002/cpt.70038 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Andriy A Gorbenko und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Human Drug Research, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Cannabidiol, Anticonvulsants, Cortical Excitability. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox–Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti‐seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti‐epileptic and sedative properties of CBD. A randomized, double‐blind, placebo‐controlled, 3‐way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD, 700 mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed‐effects model. CBD did not have significant effects on single pulse and paired pulse TMS‐EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS‐EEG at 3 hours post‐dose for 30 mg CBD, and at 3 and 5 hours post‐dose for 700 mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti‐epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Human Drug Research, Leiden, The Netherlands.
- Leiden University Medical Centre, Leiden, The Netherlands.
ORCID-Profile: Andriy A Gorbenko, Catherine M K E de Cuba, Annika A de Goede, Titiaan E Post, Roman Bohoslavsky, Pamela K Strugala, Jules A A C Heuberger, Geert Jan Groeneveld
Zitieren
APA
Gorbenko, A. A., de Cuba, C. M. K. E., de Goede, A. A., Post, T. E., Bohoslavsky, R., Strugala, P. K., Heuberger, J. A. A. C., & Groeneveld, G. J. (2026). Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3‐Way Crossover Trial. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70038
Vancouver
Gorbenko AA, de Cuba CMKE, de Goede AA, Post TE, Bohoslavsky R, Strugala PK, et al. Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3‐Way Crossover Trial. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70038
BibTeX
@article{Gorbenko2026,
author = {Gorbenko, Andriy A and de Cuba, Catherine M K E and de Goede, Annika A and Post, Titiaan E and Bohoslavsky, Roman and Strugala, Pamela K and Heuberger, Jules A A C and Groeneveld, Geert Jan},
title = {Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3‐Way Crossover Trial},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
doi = {10.1002/cpt.70038}
}
EUVIMED